SCHEMBL2701337

SCHEMBL2701337

NS(=O)(=O)N1CCC(C(=O)O)(c2ccccc2)CC1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.72
CYP2C19 P33261 2/20 0.63
MEN1 O00255 2/20 0.62
RAB9A P51151 1/20 0.62
AKR1C1 Q04828 1/20 0.58
TET3 O43151 1/20 0.55
FBXL19 Q6PCT2 1/20 0.55
CXXC5 Q7LFL8 1/20 0.55
TET1 Q8NFU7 1/20 0.55
KDM2B Q8NHM5 1/20 0.55
CXXC4 Q9H2H0 1/20 0.55
KDM2A Q9Y2K7 1/20 0.55
TSHR P16473 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
ALDH1A1 P00352 2/20 0.48
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA7 P43166 1/20 0.48
CA9 Q16790 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2701832 0.89 KMT2A (0.57) KMT2ACYP2C19MEN1RAB9AAKR1C1
SCHEMBL7066460 0.85 KMT2A (0.70) KMT2ACYP2C19MEN1RAB9AAKR1C1
SCHEMBL6498727 0.84 KMT2A (0.68) KMT2ACYP2C19MEN1RAB9AAKR1C1
SCHEMBL27683261 0.81 AKR1C1 (0.63) KMT2ACYP2C19MEN1RAB9AAKR1C1
SCHEMBL2465437 0.79 ALDH1A1 (0.78) KMT2ATSHRSMN1; SMN2ALDH1A1
SCHEMBL6502637 0.78 KMT2A (0.61) KMT2ACYP2C19MEN1RAB9AAKR1C1
SCHEMBL27381366 0.78 KMT2A (0.65) KMT2ACYP2C19MEN1RAB9AAKR1C1
SCHEMBL6391 0.78 AKR1C1 (0.83) KMT2ACYP2C19MEN1RAB9AAKR1C1
SCHEMBL31016196 0.78 AKR1C1 (0.83) KMT2ACYP2C19MEN1RAB9AAKR1C1
SCHEMBL23779147 0.77 KMT2A (0.69) KMT2ACYP2C19MEN1RAB9AAKR1C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2228065-B1 Heterocyclo inhibitors of potassium channel function BRISTOL MYERS SQUIBB CO (US) 2012-12-26 EP disclosed
EP-1501467-B1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL MYERS SQUIBB CO (US) 2012-05-09 EP disclosed
EP-2228065-A2 Heterocyclo inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2010-09-15 EP disclosed
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2009-12-17 US disclosed
US-7582654-B2 Heterocyclo inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-01 US disclosed
US-7005436-B2 Heterocyclo inhibitors of potassium channel function BRISTOL MYERS SQUIBB COMPANY (US) 2006-02-28 US disclosed
US-20060014792-A1 Heterocyclo inhibitors of potassium channel function LLOYD JOHN 2006-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014792-A1 Heterocyclo inhibitors of potassium channel function KCNJ2, KCNH2, KCNQ5 KMT2A 957/4885CYP2C19 3045/4885MEN1 3501/4885
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION KCNJ2, KCNH2, KCNQ5 KMT2A 957/4885CYP2C19 3045/4885MEN1 3501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.